Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274458 | 0.88 | DRD2 (0.35) | ALDH1A1MAPTKMT2AMEN1KDM4E | |
| SCHEMBL276375 | 0.85 | SIGMAR1 (0.34) | KMT2AMEN1KDM4E | |
| SCHEMBL1376734 | 0.80 | AOC3 (0.36) | SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3936524 | 0.79 | MAPT (0.38) | ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL275273 | 0.78 | DRD2 (0.48) | — | |
| SCHEMBL4869101 | 0.76 | MAPT (0.35) | ALDH1A1MAPTKMT2AACHEMEN1 | |
| SCHEMBL3938297 | 0.74 | — | — | |
| SCHEMBL3505646 | 0.74 | GPR84 (0.40) | KMT2AACHE | |
| SCHEMBL6282240 | 0.73 | GPR84 (0.42) | ACHE | |
| SCHEMBL4865720 | 0.72 | ALOX5 (0.34) | SMN1; SMN2ALDH1A1MAPTKMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4819280-B2 | — | — | 2011-11-24 | — | — | JP | claimed |
| EP-1274411-B1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | LUNDBECK & CO AS H (DK) | 2005-07-27 | — | — | EP | claimed |
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | AXON BIOCHEMICALS B.V. (NL) | 2004-07-15 | — | — | US | claimed |
| JP-2004500426-A | — | — | 2004-01-08 | — | — | JP | claimed |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2003-05-08 | — | — | US | claimed |
| EP-1274411-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | Axon Biochemicals B.V. (NL) | 2003-01-15 | — | — | EP | claimed |
| WO-2001078713-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | AXON BIOCHEMICALS B.V. (NL) | 2001-10-25 | — | — | WO | claimed |
| US-RE43244-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2012-03-13 | — | — | US | disclosed |
| US-RE42802-E1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2011-10-04 | — | — | US | disclosed |
| US-6998405-B2 | Parkinson's and Huntington's disease; psychoses, impotence, renal or heart failure, schizophrenia | H. LUNDBECK A/S (DK) | 2006-02-14 | — | — | US | disclosed |
| EP-1274411-B1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | LUNDBECK & CO AS H (DK) | 2005-07-27 | — | — | EP | disclosed |
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | AXON BIOCHEMICALS B.V. (NL) | 2004-07-15 | — | — | US | disclosed |
| US-6683087-B2 | TREATMENT OF PARKINSON'S DISEASE, PSYCHOSES, HUNTINGTON'S DISEASE, IMPOTENCE, RENAL FAILURE, HEART FAILURE OR HYPERTENSION | AXON BIOCHEMICALS B.V. (NL) | 2004-01-27 | — | — | US | disclosed |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | H. LUNDBECK A/S (DK) | 2003-05-08 | — | — | US | disclosed |
| EP-1274411-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | Axon Biochemicals B.V. (NL) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001078713-A1 | PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE | AXON BIOCHEMICALS B.V. (NL) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138281-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | SMN1; SMN2 1153/4885ALDH1A1 778/4885MAPT 2621/4885 |
| US-20030087948-A1 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use | ADRA1D, ABCE1, ADRA1B | SMN1; SMN2 1168/4885ALDH1A1 852/4885MAPT 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.